• Total Revenue: $38.8 million, down $2.7 million from Q3 2023.

• OA Pain Management Revenue: $24.4 million, decreased by 2%.

• International OA Pain Sales Growth: 7% increase, with year-to-date growth of 14%.

• Joint Preservation and Restoration Revenue: $12 million, decreased by 11%.

• Regenerative Solutions Growth: 17% year-over-year increase.

• Non-Orthopedic Revenue: $2.4 million, declined by 24%.

• Gross Margin: 4%, down from 60% last year, adjusted gross margin at 65%.

• Operating Expenses: $29.4 million, including $4 million in impairment charges.

• Net Loss: $29.9 million, compared to a net loss of $6.6 million in the prior year.

• Adjusted Net Loss: $3.8 million, down from adjusted net income of $3.3 million.

• Adjusted EBITDA: $5.4 million, up $700,000 from the prior year.

• Operating Cash Flow: $5 million, down from $6.5 million last year.

• Cash and No Debt: Ended the quarter with $62.4 million in cash.

• 2024 Commercial Channel Revenue Growth Guidance: 14 to 19% increase.

• 2024 OEM Channel Revenue Decline Guidance: 8 to 10% decrease.

• 2025 Commercial Channel Revenue Growth Guidance: 12 to 18% increase.

• 2025 OEM Channel Revenue Decline Guidance: 12 to 18% decrease.

• 2024 Adjusted EBITDA Guidance: Between $16 and $18 million.

• Warning! GuruFocus has detected 4 Warning Signs with ANIK.

Release Date: October 31, 2024

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Anika Therapeutics Inc (NASDAQ:ANIK) announced a strategic shift focusing on its differentiated HA-based products, targeting a $4 billion market in OA pain management and regenerative solutions.

• The company successfully launched Integrity, an HA-based scaffold for tendon repairs, achieving over 40% sequential growth in surgeries and attracting new customers.

• Anika Therapeutics Inc (NASDAQ:ANIK) filed the first module of the PMA for HiloFast, a regenerative cartilage repair solution, with plans to launch in the US by 2026.

• The company made significant progress with Cingal, acquiring the Aristospan NDA, which addresses FDA hurdles and advances the product towards US market entry.

• Anika Therapeutics Inc (NASDAQ:ANIK) expects double-digit revenue growth in its commercial channel, driven by international sales and the strength of its regenerative solutions portfolio.

Negative Points

• Anika Therapeutics Inc (NASDAQ:ANIK) reported a decline in total revenue for the third quarter, primarily due to lower sales from its J&J MedTech partner and softness in certain business segments.

• The company announced a reduction in global headcount from approximately 325 to about 225, reflecting restructuring efforts and divestitures.

• Anika Therapeutics Inc (NASDAQ:ANIK) recorded a significant net loss for the quarter, impacted by lower revenue and impairment charges related to the sale of Arthrosurface.

• The OEM channel is expected to see a revenue decline due to competitive pressures and pricing challenges in the US OA pain management market.

• The company faces ongoing challenges in stabilizing sales and increasing market access for its products sold through J&J, impacting near-term revenue forecasts.